Straits Times Index
3,310.55 -2.93 (-0.09%) Nikkei
39,069.68 +282.30 (+0.73%) Hang Seng
19,599.02 +45.41 (+0.23%) FTSE 100
8,440.32 +20.06 (+0.24%) Bitcoin USD
66,851.96 -416.04 (-0.62%) CMC Crypto 200
1,363.00 +8.58 (+0.63%)
REGN Jun 2025 1000.000 put
| Previous close | 90.30 |
| Open | 90.30 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 1,000.00 |
| Expiry date | 2025-06-20 |
| Day's range | 90.30 - 90.30 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneer
ZacksSanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
- GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
